01
The Quiet Gorilla — The Deep Dive
The canonical long-form piece. BYD analogy. Gorilla Framework. How Caplin built a distribution moat in 23 countries while Indian pharma fought for US shelf space.
Foundation
02
Financial DNA — Revenue, Margins, Returns & Cash
Seven-section forensic analysis. Revenue 8× in 10 years. PAT 13×. EBITDA 35%. ROCE, ROIC, FCF conversion, and the net cash fortress.
Financial
03
TAM & Growth Runway — Three Markets, One Engine
Full TAM build across three geographies. LatAm $75B→$102B. US injectables $18B→$43B. Africa $27B→$37B. Combined $170B+ at sub-0.2% penetration.
Market Sizing
04
The Man Who Takes No Salary — Management Forensic
Zero salary. Zero dilution. Zero debt in 35 years. Six tracked commitments — four kept, one exceeded. KMP pay at 1.35% of PAT.
Management
05
Find the Toll Booth — Moat Profile & Bottleneck Screen
Five moat layers classified and scored. LatAm distribution 9.2/10. Regulatory licences 9.0/10. Vertical integration 8.5/10. Composite 8.5/10.
Moat Analysis
06
Three Masters, One Verdict — Valuation Tribunal
If Munger, Damodaran, and Terry Smith each valued Caplin Point — what would they say? Three frameworks converge on one conclusion.
Special Report
07
Why Caplin Has No Real Peers
The category error in standard peer tables. The right archetype is distribution-moat businesses in underserved geographies — not Indian pharma exporters.
Valuation
08
The Risk Register — A Forensic Threat Assessment
Nine risks assessed. Thesis killers defined. Exit signals established. Three material risks, none fatal if the moat structure holds.
Risk
09
Return Profile — What ₹1,699 Buys You to 2035
Four EPS scenarios. Bear 12% CAGR → Bull 33% CAGR. The return map across multiple P/E re-rating paths over a 10-year horizon.
Returns
10
Quarterly Monitoring Dashboard
Post-investment tracking. Green/amber/red thresholds for every thesis variable. Updated Q3 FY26. The discipline to watch what matters.
Live Document